Real-World Low-Density Lipoprotein Cholesterol Control After Transitioning From Evolocumab to Inclisiran
{{output}}
Background: Inclisiran is a siRNA therapy that provides sustained reduction in low-density lipoprotein cholesterol (LDL-C) with twice-yearly dosing, but real-world data after switching from PCSK9 monoclonal antibodies remain limi... ...
